PT948965E - STABILIZABLE MEDICINAL COMPOSITIONS CONTAINING A 4,5-EPOXYMORPHINAN DERIVATIVE - Google Patents

STABILIZABLE MEDICINAL COMPOSITIONS CONTAINING A 4,5-EPOXYMORPHINAN DERIVATIVE

Info

Publication number
PT948965E
PT948965E PT98931040T PT98931040T PT948965E PT 948965 E PT948965 E PT 948965E PT 98931040 T PT98931040 T PT 98931040T PT 98931040 T PT98931040 T PT 98931040T PT 948965 E PT948965 E PT 948965E
Authority
PT
Portugal
Prior art keywords
stabilizable
medicinal compositions
compositions containing
epoxymorphinan derivative
epoxymorphinan
Prior art date
Application number
PT98931040T
Other languages
Portuguese (pt)
Inventor
Michio Hara
Yasuhide Horiuchi
Nobuyuki Hanamura
Ryoji Yoshii
Takao Aoki
Original Assignee
Toray Industries
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries filed Critical Toray Industries
Publication of PT948965E publication Critical patent/PT948965E/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Abstract

Stable medicinal compositions characterized by containing 4,5-epoxymorphinane derivatives and at least one member selected from among water-soluble antioxidants, fat-soluble antioxidants, synergists, saccharides and surfactants.
PT98931040T 1997-07-11 1998-07-10 STABILIZABLE MEDICINAL COMPOSITIONS CONTAINING A 4,5-EPOXYMORPHINAN DERIVATIVE PT948965E (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP18695097 1997-07-11

Publications (1)

Publication Number Publication Date
PT948965E true PT948965E (en) 2004-08-31

Family

ID=16197570

Family Applications (1)

Application Number Title Priority Date Filing Date
PT98931040T PT948965E (en) 1997-07-11 1998-07-10 STABILIZABLE MEDICINAL COMPOSITIONS CONTAINING A 4,5-EPOXYMORPHINAN DERIVATIVE

Country Status (15)

Country Link
US (1) US6372755B2 (en)
EP (1) EP0948965B1 (en)
JP (3) JP3617055B2 (en)
KR (1) KR100514963B1 (en)
CN (1) CN100379419C (en)
AT (1) ATE268178T1 (en)
AU (1) AU740404B2 (en)
CA (1) CA2265767C (en)
DE (1) DE69824277T2 (en)
DK (1) DK0948965T3 (en)
ES (1) ES2217563T3 (en)
NO (1) NO318831B1 (en)
PT (1) PT948965E (en)
TW (1) TWI285644B (en)
WO (1) WO1999002158A1 (en)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ899400A0 (en) * 2000-07-26 2000-08-17 Csl Limited A method of stabilisation and compositions for use therein
TWI282275B (en) * 2000-08-17 2007-06-11 Control Ox Oy Plant-derived and synthetic phenolic compounds and plant extracts, effective in the treatment and prevention of chlamydial infections
JP4880813B2 (en) * 2000-10-26 2012-02-22 第一三共株式会社 Anti-inflammatory analgesic composition for external use
US20140271788A1 (en) 2013-03-15 2014-09-18 Monosol Rx, Llc Sublingual and buccal film compositions
DE10161149B4 (en) * 2001-12-12 2007-03-08 Ursapharm Arzneimittel Gmbh & Co. Kg Use of heparin-containing ophthalmic agent
DE10161110A1 (en) * 2001-12-12 2003-06-26 Ursapharm Arzneimittel Gmbh Pharmaceutical composition for ophthalmic and rhinological use
ZA200409537B (en) 2003-01-31 2006-10-25 Yamanouchi Pharma Co Ltd Stable solid medicinal composition for oral administration
EP1735004A4 (en) * 2004-04-07 2011-11-09 Resveratrol Partners Llc Dietary supplement and method of processing same
US8288362B2 (en) 2004-05-07 2012-10-16 S.K. Pharmaceuticals, Inc. Stabilized glycosaminoglycan preparations and related methods
CA2565944C (en) * 2004-05-07 2011-07-19 S.K. Pharmaceuticals, Inc. Stabilized hyaluronan preparations and related methods
WO2006024138A1 (en) * 2004-08-30 2006-03-09 Taro Pharmaceutical Industries Ltd. A thermoreversible pharmaceutical formulation for anti-microbial agents comprising poloxamer polymers and hydroxy fatty acid ester of polyethylene glycol
WO2006067605A1 (en) * 2004-12-23 2006-06-29 Ranbaxy Laboratories Limited Stable pharmaceutical compositions of tiagabine and processes for their preparation
CN101150956B (en) * 2005-01-27 2013-04-17 埃里莫斯医药品有限公司 Formulations for injection of catecholic butanes, including NDGA compounds, into animals
EP1845787B1 (en) * 2005-01-27 2015-04-15 Erimos Pharmaceuticals LLC Formulations for injection of catecholic butanes, including ndga compounds, into animals
TWI286941B (en) * 2005-07-27 2007-09-21 Anagen Therapeutics Inc Stabilized pharmaceutical and cosmetic composition of catechins or derivatives thereof
KR101491656B1 (en) 2007-04-26 2015-02-09 도레이 카부시키가이샤 Stable solid preparation comprising 4,5-epoxymorphinan derivative
WO2008143240A1 (en) * 2007-05-21 2008-11-27 Toray Industries, Inc. Oral preparation comprising specific organic acid, and method for improvement in elution property and chemical stability of oral preparation
CN101658489B (en) * 2008-08-27 2011-11-23 海南四环心脑血管药物研究院有限公司 Nalmefene hydrochloride injection and preparation method thereof
ES2660001T3 (en) * 2008-10-24 2018-03-20 Toray Industries, Inc. Stable tablet containing a 4,5-epoxymorphinan derivative
TWI455733B (en) 2009-03-30 2014-10-11 Toray Industries A coating tablet collapsible in the oral cavity
MX2011012735A (en) * 2009-06-04 2012-02-28 Alk Ag Stabilised composition comprising at least one adrenergic compound.
WO2012054831A2 (en) 2010-10-21 2012-04-26 Rtu Pharmaceuticals, Llc Ready to use ketorolac formulations
JP5750278B2 (en) * 2011-02-28 2015-07-15 東洋カプセル株式会社 Candesartan cilexetil capsule filling composition
WO2013070656A1 (en) * 2011-11-07 2013-05-16 Navinta Llc Sustained release suspension preparation for dextromethorphan
US8916528B2 (en) 2011-11-16 2014-12-23 Resveratrol Partners, Llc Compositions containing resveratrol and nucleotides
JP6064252B2 (en) * 2012-01-19 2017-01-25 三笠製薬株式会社 Pruritus-improving transdermal patch
JP6247118B2 (en) * 2014-03-05 2017-12-13 東海カプセル株式会社 Capsule filling composition
JP6630343B2 (en) * 2015-03-19 2020-01-15 第一三共株式会社 Solid preparations containing antioxidants
WO2016148264A1 (en) 2015-03-19 2016-09-22 第一三共株式会社 Solid preparation containing colorant
JP5918895B1 (en) * 2015-05-21 2016-05-18 富士カプセル株式会社 Nalfurafine hydrochloride-containing capsule formulation
TW201707703A (en) * 2015-06-04 2017-03-01 Tokai Capsule Co Ltd Soft capsule preparation
WO2018021518A1 (en) * 2016-07-29 2018-02-01 東レ株式会社 Solid preparation having improved light stability
JP6131379B1 (en) * 2016-12-28 2017-05-17 森下仁丹株式会社 Formulation containing 4,5-epoxymorphinan derivative
EP3603643B1 (en) * 2017-03-31 2021-09-15 Toray Industries, Inc. Tableted medicinal composition comprising nalfurafine
WO2019171333A1 (en) 2018-03-08 2019-09-12 Victoria Link Ltd Treatment of demyelinating diseases
US11198831B2 (en) 2019-01-31 2021-12-14 Kvi Llc Lubricant for a device
CN113614089A (en) 2019-03-29 2021-11-05 人福医药美国公司 Novel morphinans useful for treating medical conditions
EP4062973A4 (en) * 2019-11-20 2023-11-29 Shionogi & Co., Ltd 6,7-unsaturated-7-carbamoyl morphinan derivative-containing solid formulation
AU2022292554A1 (en) 2021-06-14 2024-01-04 Scorpion Therapeutics, Inc. Urea derivatives which can be used to treat cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2765694B2 (en) 1988-01-29 1998-06-18 日清バーディシェ株式会社 Stable compositions of oxidation-sensitive compounds
GB8820327D0 (en) 1988-08-26 1988-09-28 May & Baker Ltd New compositions of matter
ES2121988T3 (en) * 1992-01-23 1998-12-16 Toray Industries DERIVATIVE OF MORFINANO AND MEDICINAL USE.
NZ268969A (en) * 1993-07-23 1997-06-24 Toray Industries Morphinan derivatives and pharmaceutical compositions
US5948389A (en) * 1995-06-07 1999-09-07 El Khoury & Stein, Ltd. Method of enhancing the analgesic efficacy of locally and topically administered opioids and other local anesthetics
DE29719704U1 (en) 1997-02-14 1998-01-22 Goedecke Ag Stable preparations of naloxone hydrochloride

Also Published As

Publication number Publication date
DE69824277D1 (en) 2004-07-08
JP4311369B2 (en) 2009-08-12
JP2005247866A (en) 2005-09-15
AU740404B2 (en) 2001-11-01
ATE268178T1 (en) 2004-06-15
US6372755B2 (en) 2002-04-16
KR20000068528A (en) 2000-11-25
JP2005002123A (en) 2005-01-06
CN1237106A (en) 1999-12-01
AU8128298A (en) 1999-02-08
NO991152L (en) 1999-05-10
KR100514963B1 (en) 2005-09-15
EP0948965B1 (en) 2004-06-02
WO1999002158A1 (en) 1999-01-21
EP0948965A4 (en) 2002-10-16
JP3743449B2 (en) 2006-02-08
NO991152D0 (en) 1999-03-10
CN100379419C (en) 2008-04-09
ES2217563T3 (en) 2004-11-01
DE69824277T2 (en) 2004-09-23
JP3617055B2 (en) 2005-02-02
CA2265767C (en) 2007-12-04
NO318831B1 (en) 2005-05-09
US20010004637A1 (en) 2001-06-21
CA2265767A1 (en) 1999-01-21
EP0948965A1 (en) 1999-10-13
TWI285644B (en) 2007-08-21
DK0948965T3 (en) 2004-07-05

Similar Documents

Publication Publication Date Title
PT948965E (en) STABILIZABLE MEDICINAL COMPOSITIONS CONTAINING A 4,5-EPOXYMORPHINAN DERIVATIVE
DK0698393T3 (en) 3 - / - menthoxypropane-1,2-diol as a solubilizer and topical preparation containing the same
CY1105112T1 (en) ANTI-HUMAN VIRUS FORMULATIONS, PRESSED SPINOSYN
MY118151A (en) Pharmaceutical formulations containing voriconazole.
PL360294A1 (en) Propane-1,3-dione derivatives
DZ2569A1 (en) Substituted 1,2,3,4-tetrahydronaphthalene derivatives.
PT955042E (en) PHARMACEUTICAL COMPOSITION BASED ON ESTROGEN AND PROGESTERONE
IL134961A0 (en) Carboxamidothiazole derivatives, preparation, pharmaceutical compositions containing them
ATE225341T1 (en) PACLITAXELE SUBSTITUTED BY THIO IN 6 POSITION
HUP9902455A3 (en) 6-phenylpyridyl-2-amine derivatives, pharmaceutical compositions containing them
DK0588539T3 (en) Stabilized pharmaceutical preparations containing derivatives of vitamins D2 and D3
PL346166A1 (en) Pesticidal compositions comprising 1,2,3-benzothiadiazole derivatives
ATE212635T1 (en) 1,3,8-TRIAZASPIRO(4,5)DECAN-4-ON DERIVATIVES
IS5730A (en) Substituted thiazolo-pyridazine derivatives, pharmaceutical formulations thereof
CY2313B1 (en) Rapamycin formulations for oral administration.
ZA9810637B (en) Formulations comprising dissolved paroxetine.
EP1018336A4 (en) Carcinostatics
ZA200006557B (en) Agents for combating plant pests.
AR008474A1 (en) DERIVATIVE OF 9-DIHYDROERYTHROMYCIN A 6.9; 11,12-DICICLOCARBONATO, PHARMACEUTICAL COMPOSITION AND BACTERICIDE PREPARATION THAT CONTAIN IT AND ITS USE
DE69818492D1 (en) 7-methylthiooxomethyl- und 7-methylthiodioxomethyl-paclitaxele
AU5468101A (en) Novel p-aminophenols and colorants containing said compounds
BG104692A (en) Extended release tiagabine formulation
HK1062437A1 (en) Pharmaceutical compositions comprising 2,3-diaryl-pyrazoloÄ1,5-bÜpyridazine derivatives.
ATE230602T1 (en) PREPARATION CONTAINING VX 478 AND A WATER-SOLUBLE VITAMIN E COMPOUND SUCH AS VITAMIN E-TPGS
ITMI952125A1 (en) BENZO DERIVATIVES (B) DECALIN-5, 10-DIONI-2, 3, 4-ALFA, 10-ALFA-DEIDRO FOR ANTI-CANCER ACTIVITY